Add to balance / Manage account | Not logged in |
3/6/2023 | BKCVEMHY | S&P assigns BB- to Teva notes |
3/3/2023 | BKCVDDEMIGPV | Market Commentary: Junk secondary strengthens; Navacord tucked away; Frontier lifted; Teva moves higher |
3/2/2023 | BKCVDDEMIGPV | Market Commentary: Jones DesLauriers prices; Teva, Ritchie, Alteryx at premiums; junk funds out $2.31 billion |
3/1/2023 | BKCVEMGNHY | Fitch assigns BB- to Teva notes |
11/14/2019 | BKCVEM | Moody’s rates Teva notes Ba2 |
3/16/2018 | BKCVEMIG | Fitch rates Teva Pharmaceutical notes BB/RR4 |
3/1/2018 | BKCVEMIG | Fitch rates Teva notes BB |
2/28/2018 | BKCVEM | S&P rates Teva notes BB |
2/28/2018 | BKCVEM | Moody’s applies Ba2 to Teva notes |
7/18/2016 | BKCVEMIG | Moody’s rates Teva notes Baa2 |